Risk of Severe COVID-19 in those with IMIDs
In a recent study, researchers evaluated whether the patients suffering from various immune-mediated inflammatory diseases (IMIDs) and malignancies had an increased risk of severe COVID-19.
Read More »
Rheumatoid Arthritis
In Rheumatoid Arthritis (RA), the most common chronic inflammatory joint disease, autoantibodies attack the joints and cause joint destruction. Below are COVID news and research updates that specifically relate to RA.
COVID-19 Outcomes in Myasthenia Gravis Patients
Symptoms related to COVID-19 infections such as systemic inflammation, neurological complications, and a dysregulated immune response can lead to worse clinical outcomes for patients with Myasthenia Gravis (MG). Researchers conducted an observational retrospective study to measure COVID-19 outcomes in these patients, especially in regard to exacerbation of MG symptoms.
Read More »SLE Flares Post COVID-19 Vaccine
A study in Japan analyzed the association between mRNA Covid-19 vaccination and medium-term SLE flare-ups. At 30 days after completion of a primary series, the rate of mild or moderate SLE flares was 20.3% within the vaccinated group, versus 23.3% in the unvaccinated group. Flare rates at 60 and 90 days were similar between both groups.
Read More »RA and SLE-related Autoreactivities Present in Those with COVID-19
A recent study found antibodies associated with RA and SLE in hospital patients with severe COVID-19. Additionally, one third of long Covid patients included in the study were observed to have elevated levels of autoantibodies for months post initial-infection.
Read More »